Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing King-Friend Biochemical Pharmaceutical Co Buyback Yield % Chart
Nanjing King-Friend Biochemical Pharmaceutical Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Nanjing King-Friend Biochemical Pharmaceutical Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing King-Friend Biochemical Pharmaceutical Co Buyback Yield % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) has a Buyback Yield % of 0.00 as of Aug. 09, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Nanjing King-Friend Biochemical Pharmaceutical Co and its competitors. According to the industry distribution chart, Nanjing King-Friend Biochemical Pharmaceutical Co ranks #999999 out of 277 companies in the Drug Manufacturers industry.
Is Nanjing King-Friend Biochemical Pharmaceutical Co's Buyback Yield % too high?
Nanjing King-Friend Biochemical Pharmaceutical Co's current Buyback Yield % is 0.00. Based on the distribution chart, Nanjing King-Friend Biochemical Pharmaceutical Co ranks #999999 out of 277 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nanjing King-Friend Biochemical Pharmaceutical Co has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanjing King-Friend Biochemical Pharmaceutical Co's Buyback Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Nanjing King-Friend Biochemical Pharmaceutical Co ranks #999999 out of 277 companies for Buyback Yield %. This places Nanjing King-Friend Biochemical Pharmaceutical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Nanjing King-Friend Biochemical Pharmaceutical Co and its competitors. Nanjing King-Friend Biochemical Pharmaceutical Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing King-Friend Biochemical Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥12.78, compared to a current price of ¥8.10 — trading 36.6% below its estimated fair value. The current Buyback Yield % is 0.00. Nanjing King-Friend Biochemical Pharmaceutical Co's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707), the current Buyback Yield % is 0.00 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Overvalued in 2026?
Based on GuruFocus' analysis, Nanjing King-Friend Biochemical Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥8.10 is trading 36.6% below its estimated GF Value™ of ¥12.78.
GuruFocus considers Nanjing King-Friend Biochemical Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for SHSE:603707:
Buyback Yield %: 0.00
GF Value™: ¥12.78 vs. price of ¥8.10 (36.6% below fair value)
No single metric tells the full story. See the SHSE:603707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.
66GF Score
Get the complete analysis for SHSE:603707
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603707 has been successfully added to your 
